Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af JNJ-89862175 til behandling af avancerede solide tumorer

2. november 2026 opdateret af: Janssen Research & Development, LLC

En fase 1-studie af JNJ-89862175, et antistof-lægemiddelkonjugat mod ectonukleotid pyrofosfatase/fosfodiesterase familiemedlem 3, til avancerede solide tumorer

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

360

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Florida
      • Orlando, Florida, Forenede Stater, 32803
        • Rekruttering
        • AdventHealth Orlando
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital Cancer Center
    • Texas
      • Irving, Texas, Forenede Stater, 75039
        • Rekruttering
        • NEXT Oncology
      • Lyon, Frankrig, 69373
        • Rekruttering
        • Centre Leon Berard
      • Villejuif, Frankrig, 94805
        • Rekruttering
        • Gustave Roussy
      • Seoul, Sydkorea, 06351
        • Rekruttering
        • Samsung Medical Center
      • Seoul, Sydkorea, 03722
        • Rekruttering
        • Severance Hospital Yonsei University Health System

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
  • Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom

Exclusion Criteria:

  • Active central nervous system (CNS) involvement unless clinically stable
  • History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
  • History of solid organ or hematologic stem cell transplantation
  • Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
  • Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: JNJ-89862175

Participants will receive JNJ-89862175 in Part 1 to determine the recommended phase 2 doses (RP2Ds). Dose-escalation and de-escalation will be based on study evaluation team (SET) decision. In Part 2, participants will receive JNJ-89862175 at the RP2Ds determined in Part 1.

JNJ-89862175 will be administered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Tidsramme: Up to 21 days

The DLTs are specific adverse events that includes high grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation.

Up to 21 days
Part 1: Number of Participants with Adverse Events (AEs) by Severity
Tidsramme: Up to 2 years and 10 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 2 years and 10 months
Part 2: Number of Participants with Adverse Events (AEs) by Severity at RP2D
Tidsramme: Up to 2 years and 10 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 2 years and 10 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR)
Tidsramme: Up to 2 years and 10 months

ORR is defined as the percentage of participants who have best overall response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v.) 1.1.

Up to 2 years and 10 months
Progression Free Survival (PFS)
Tidsramme: Up to 2 years and 10 months

PFS is defined as the time from the first dose of JNJ-89862175 to either disease progression according to RECIST v. 1.1, or death due to any cause, whichever comes first.

Up to 2 years and 10 months
Duration of Response (DOR)
Tidsramme: Up to 2 years and 10 months

DOR is defined as the time from the date of initial documentation of a response to the date of first documented evidence of disease progression according to RECIST v. 1.1, or death due to any cause, whichever occurs first.

Up to 2 years and 10 months
Maximum Plasma Concentration (Cmax) for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Tidsramme: Up to 2 years and 10 months

Serum samples will be analyzed to determine Cmax of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite.

Up to 2 years and 10 months
Observed Plasma Concentration Immediately Before Next Dose Administration (Ctrough) of JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Tidsramme: Up to 2 years and 10 months

Ctrough of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported.

Up to 2 years and 10 months
Time to Reach Cmax (Tmax) for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Tidsramme: Up to 2 years and 10 months

Tmax defined as the the time to reach maximum observed plasma concentration of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported.

Up to 2 years and 10 months
Area Under the Plasma Concentration - Time (AUC [0-t]) Curve for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Tidsramme: Up to 2 years and 10 months

AUC (0-t) defined as area under the plasma concentration-time curve during a dosing interval of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported.

Up to 2 years and 10 months
Accumulation Ratio of JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Tidsramme: Up to 2 years and 10 months

Accumulation ratio of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported.

Up to 2 years and 10 months
Number of Participants With Anti JNJ-89862175 Antibodies
Tidsramme: Up to 2 years and 10 months

Serum samples will be analyzed for the detection of anti-JNJ-89862175 antibodies using a validated assay method.

Up to 2 years and 10 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. oktober 2025

Primær færdiggørelse (Anslået)

15. december 2026

Studieafslutning (Anslået)

15. august 2028

Datoer for studieregistrering

Først indsendt

30. oktober 2025

Først indsendt, der opfyldte QC-kriterier

30. oktober 2025

Først opslået (Faktiske)

31. oktober 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 89862175LUC1001
  • 89862175LUC1001 (Anden identifikator: Janssen Research & Development, LLC)
  • 2025-521407-52-00 (Registry Identifier: EUCT number)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner